Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021
February 18 2021 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”), a technology company providing comprehensive testing
solutions through its scalable technology platform, today announced
that it will release its fourth quarter and full year 2020
financial results after the market closes on Thursday March 4,
2021. The company’s Chairman and Chief Executive Officer Ming
Hsieh, Chief Financial Officer Paul Kim and Chief Commercial
Officer Brandon Perthuis will host a conference call for the
investment community the same day at 4:30 PM ET (1:30 PM PT) to
discuss the results and answer questions.
The call can be accessed through a live audio
webcast in the Investors section of the company’s website,
http://ir.fulgentgenetics.com, and through a live conference call
by dialing (855) 321-9535 using the conference ID 7669989. An audio
replay will be available in the Investors section of the company’s
website or by calling (855) 859-2056 using passcode 7669989 through
March 11, 2021.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology
platform has created a broad, flexible test menu and the ability to
continually expand and improve its proprietary genetic reference
library while maintaining accessible pricing, high accuracy and
competitive turnaround times. Combining next generation sequencing
(“NGS”) with its technology platform, the Company performs
full-gene sequencing with deletion/duplication analysis in an array
of panels that can be tailored to meet specific customer needs. In
2019, the Company launched its first patient-initiated product,
Picture Genetics, a new line of at-home screening tests that
combines the Company’s advanced NGS solutions with actionable
results and genetic counseling options for individuals. Since March
2020, the Company has commercially launched several tests for the
detection of SARS-CoV-2, the virus that causes the novel
coronavirus (“COVID-19”), including NGS and reverse transcription
polymerase chain reaction (“RT-PCR”) - based tests. The Company has
received Emergency Use Authorization (“EUA”) from the U.S. Food and
Drug Administration (“FDA”) for the RT-PCR-based tests for the
detection of SARS-CoV-2 using upper respiratory specimens (nasal,
nasopharyngeal, and oropharyngeal swabs) and for the at-home
testing service through Picture Genetics. A cornerstone of the
Company’s business is its ability to provide expansive options and
flexibility for all clients’ unique testing needs through a
comprehensive technology offering including cloud computing,
pipeline services, record management, web portal services, clinical
workflow, sequencing as a service and automated lab services.
Investor Relations Contacts:The
Blueshirt GroupNicole Borsje, 415-217-2633;
nicole@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Apr 2023 to Apr 2024